Preventing and treating vitamin A deficiency is the first step in preventing systemic and ocular complications, including xerophthalmia, according to Alfred Sommer, MD, MHS.
Eculizumab (Soliris, Alexion) has been cleared by the U.S. Food and Drug Administration to treat neuromyelitis optica spectrum disorder (NMOSD) in adults with a specific biomarker.
In this video, Robert Maloney, MD, discusses the efficacy of the iDESIGN system (Johnson & Johnson Vision,) and the positive outcomes patients have experienced.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
